MAPT and Alzheimer disease: Brain sEH was recentlyvalidated as a novel target of interest for AD treatment.22−25 sEH inhibitors have shown beneficial effects in two different mousemodels of AD, SAMP8 and 5×FAD mice, in which they rescued cognitiveimpairment and reduced neuroinflammation, and other key pathologicalhallmarks (tau hyperphosphorylation and amyloid burden).22